A 2-part Phase 2 Study of Safety, Pharmacokinetics and Biomarkers in Children With Duchenne Muscular Dystrophy Including a Randomized, Double-Blind, Placebo-Controlled Part A, Followed by an Open-Label Part B

Trial ID: NCT05540860

Interventional - Phase 2 - Active, not recruiting

The LYNX study is a 2-part, multicenter, Phase 2 study of safety, pharmacokinetics and biomarkers in children with Duchenne muscular dystrophy including a randomized, double-blind, placebo-controlled part A, followed by an open-label part B.

Conditions

• Duchenne Muscular Dystrophy

Interventions

• Sevasemten Dose 1
• Sevasemten Dose 2
• Sevasemten Dose 3
• Sevasemten Dose 4
• Sevasemten Dose 5
• Placebo

Eligibility

Inclusion criteria

• 1. A documented mutation on the DMD gene and phenotype consistent with Duchenne muscular dystrophy.
• 2. Able to complete the stand from supine in ≤ 10 seconds and able to perform the 4-stair climb in \< 10 seconds at the Screening visit.
• 3. Body weight greater than or equal to 15 kg at the Screening visit.
• For Cohorts 1, 2, 3, 4 and 5:
• Aged 4-9 years on a stable dose of corticosteroids for a minimum of 6 months prior to the Baseline visit.
• For Cohort 2 Non-Steroid (Cohort 2NS):
• Aged 4-7 years not on corticosteroids within 6 months prior to the Baseline visit.
• Key Common

Exclusion criteria

• 1. Medical history or clinically significant physical exam/laboratory result that, in the opinion of the investigator, would render the participant unsuitable for the study. This includes venous access that would be too difficult to facilitate repeated blood testing.
• 2. A forced vital capacity \< 60% predicted at the Screening visit for those participants who are \> 8 years old at Screening.
• 3. A cardiac echocardiography showing left ventricular ejection \< 45% at the Screening visit.
• 4. Receipt of an investigational drug within 30 days or 5 half-lives (whichever is longer) of the Screening visit in the present study.
• 5. Receipt of a stable dose of an approved exon-skipping therapy with a treatment duration of less than 1 year prior to the Screening visit.
• For Cohort 2 Non-Steroid (Cohort 2NS):
• Receipt of oral corticosteroids for the treatment of Duchenne muscular dystrophy in the previous 6 months. Participants will not be tapered off steroids for the purpose of this study and oral corticosteroids for the treatment of Duchenne muscular dystrophy may be initiated after the Week 16 visit.

Sponsor

Edgewise Therapeutics, Inc.

Source: ClinicalTrials.gov

Search more clinical trials on myTomorrows